Increased ERCC Expression Correlates with Improved Outcome of Patients Treated with Cisplatin as an Adjuvant Therapy for Curatively Resected Gastric Cancer

PURPOSE: It has been reported that the overexpression of the excision repair cross-complementing 1 (ERCC1) gene, which is essential for the repair of cisplatin (CDDP)-DNA adducts, negatively influences the effectiveness of CDDP-based therapy for primary gastric cancer. We investigated whether the ER...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Baek, Sun Kyung, Kim, Si-Young, Lee, Jae Jin, Kim, Yoon Wha, Yoon, Hwi Joong, Cho, Kyung Sam
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Korean Cancer Association 2006
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2741659/
https://ncbi.nlm.nih.gov/pubmed/19771254
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2006.38.1.19
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak